Navigation Links
Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
Date:2/27/2013

Cary, NC (PRWEB) February 27, 2013

PharmaDirections congratulates Hyperion Therapeutics on achieving a NDA approval for their RAVICTI™ (glycerol phenylbutyrate) Liquid for Treatment of Urea Cycle Disorders. PharmaDirections is proud to have been involved as a pharmaceutical development partner and to have helped in the development of Hyperion's first product to complete full clinical development.

Hyperion has achieved a major milestone for adult and pediatric patients =2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of UCD. In clinical studies, RAVICTI kept ammonia at safe levels throughout the day and night and over the long-term (1 year).

PharmaDirections participated in this important program by providing CMC and PK support over the past four years. They were responsible for overseeing the development of the API manufacturing process. They used their process chemistry expertise to review the synthetic scheme and to propose improvements for API synthesis development and optimization that led to improvements in the manufacturing process. Their scientific experts led efforts in formulation development, bioanalytical method development and pharmacokinetic analyses. Their regulatory affairs experts helped in the NDA preparation process by authoring and completing specific areas of the CMC section. PharmaDirections was proud to be a part of this team.

About PharmaDirections

PharmaDirections is a pharmaceutical consulting and project management company with special expertise in preclinical development, Chemistry and Manufacturing Controls, and regulatory affairs. They design and direct outsourced R&D programs for biotech and pharmaceutical firms. They allow virtual biotech firms to achieve their development milestones on time and on budget because of PharmaDirections' long term relationships with CRO and CMOs, and the extensive scientific expertise.

For more information please visit http://www.PharmaDirections.com.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. For more information, please visit http://www.hyperiontx.com.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10442980.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
2. Watsons Generic Yaz(R) Receives FDA Approval
3. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
4. FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length
5. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
6. Watsons Generic BONIVA® 150mg Receives FDA Approval
7. Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors
8. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
9. FDA Issues Orphan Status Approval for PermaDerm®
10. West Wireless Health Institute Applauds House Passage of Bill to Streamline FDA Medical Device Approval Process, Expedite Mobile Medical App Guidance
11. Lupin Receives FDA Approval for Generic LYRICA(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... for information (RFI) issued by the Office of the National Coordinator for Health ... experience, and determines if clinically relevant data were available when and where it ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis ... cruciate ligament in her left knee. Lady’s owner Hannah sought the help of Dr ... veterinary surgeon, to repair her cruciate ligament and help with the pain of Lady’s ...
(Date:5/24/2016)... , May 24, 2016   MedyMatch Technology Ltd ... with artificial intelligence, real-time decision support tools in the emergency ... at the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... Israel,s 15th National Life Sciences and Technology ... the David Intercontinental Hotel in Tel Aviv, Israel ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and ... the South Texas Blood & Tissue Center, blood donations are on the decline. In fact, ... they are down 21 percent in South Texas in the last four years alone. , ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):